Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.

ABSTRACT:

Objective

To examine the association between first-trimester angiotensin-converting enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central nervous system malformations.

Methods

We used a cohort of completed pregnancies linked to liveborn neonates derived from Medicaid claims from 2000 to 2010. We examined the risk of malformations associated with first-trimester exposure to an ACE inhibitor. Propensity score-based methods were used to control for potential confounders including maternal demographics, medical conditions, exposure to other medications, and measures of health care utilization.

Results

The cohort included 1,333,624 pregnancies, of which 4,107 (0.31%) were exposed to ACE inhibitors during the first trimester. The pre

SUBMITTER: Bateman BT 

PROVIDER: S-EPMC5177460 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature